Credit Assessment: BIOXYDYN LIMITED

1. Credit Opinion: CONDITIONAL

Recommendation with significant reservations. Any credit facility should be strictly limited, adequately secured, and subject to robust covenant package. The company presents elevated risk due to persistent operating losses, negative working capital, and a precarious liquidity position. Approval would require parental/investor guarantees and enhanced monitoring terms.

2. Financial Strength

Balance Sheet Assessment: WEAK

Key Concerns:

• Accumulated losses are substantial: The P&L reserve stands at (£2,517,488), marginally improved from (£2,534,588). While the £17,100 improvement suggests the company may have moved toward breakeven, cumulative losses remain deeply侵蚀ed.

• Asset quality is poor: £1,000,000 of the £1,002,821 in fixed assets comprises capitalised development costs (intangible assets). These represent historic R&D expenditure with uncertain realisable value. Tangible assets amount to only £2,821.

• Share premium reliance: The £3,240,162 share premium account indicates historical equity injections from institutional investors (MTI Partners, North West Fund, NWF Biomedical). This capital has been substantially consumed by accumulated losses.

• Long-term trajectory is concerning: Net assets have deteriorated dramatically from £2,493,824 (2015) to £724,307 (2024), representing a 71% erosion over the period.

3. Cash Flow Assessment

Liquidity Position: CRITICAL

Critical Findings:

• Negative working capital: The company cannot cover its short-term obligations from current assets. The current ratio of 0.76:1 falls well below acceptable thresholds for lending.

• Cash has halved: Cash declined from £47,967 to £21,966 (54% reduction), leaving minimal liquidity buffer.

• Deferred income/accruals dominate current liabilities: £237,324 (77%) of current liabilities comprise accruals and deferred income. This likely represents grant funding received in advance or contracted service obligations, which provides some stability but limits financial flexibility.

• Trade creditors reduced significantly: Down from £55,310 to £22,845, which may indicate reduced purchasing activity or supplier pressure for faster payment.

• Long-term other creditors of £197,779: This substantial balance (likely investor loans or related-party facilities) provides some runway but represents obligation that will need to be addressed.

• Debt service capacity is questionable: With minimal cash and no visible profit generation, the company's ability to service additional debt is severely constrained.

4. Monitoring Points

Priority Metrics for Ongoing Surveillance:

1. Cash runway: Monitor monthly cash position relative to burn rate. At current levels, cash reserves are perilously thin.

2. Revenue visibility: Request management accounts to understand turnover trends and contract pipeline. The filed accounts suppress the P&L, making revenue and profitability assessment impossible from public data alone.

3. Deferred income composition: Clarify what constitutes the £237,324 in accruals and deferred income—grant income, customer advances, or accrued costs. This materially affects risk assessment.

4. Long-term creditor nature: Understand terms of the £197,779 in other creditors due after one year. If these are convertible investor loans, assess conversion risk and subordination terms.

5. Development asset recoverability: The £1,000,000 capitalised development cost should be reviewed for impairment indicators. No amortisation was charged in the period, and the asset has remained static at £1m since at least 2023.

6. Investor commitment: Confirm ongoing support from MTI Partners, North West Fund, and NWF Biomedical. Any withdrawal of investor support would likely render the company insolvent.

7. Employee headcount: Staff reduced from 8 to 7—monitor for further reductions which may signal financial distress or loss of critical capability.

8. Filing compliance: Accounts are up to date and confirmation statement filed. Maintain watch for any filing delays which could indicate governance concerns.